- Latest available (Revised)
- Original (As made)
The Medical Devices (Northern Ireland Protocol) Regulations 2021
You are here:
- UK Statutory Instruments
- 2021 No. 905
- SCHEDULE 3
What Version
Advanced Features
- Show Geographical Extent(e.g. England, Wales, Scotland and Northern Ireland)
- Show Timeline of Changes
More Resources
Changes to legislation:
There are currently no known outstanding effects for the The Medical Devices (Northern Ireland Protocol) Regulations 2021, SCHEDULE 3.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Regulation 23
SCHEDULE 3N.I.Provisions breach of which is an offence under regulation 23
This schedule has no associated Explanatory Memorandum
Commencement Information
I1Sch. 3 in force at 27.7.2021, see reg. 1(2)
[F1Table 1
| Regulation | Title of the regulation |
|---|---|
| 5 | Reprocessing of single-use devices |
| 6 | Requirement on health institutions relating to implanted devices |
| 7 | Provision of information relating to custom-made devices |
| 9 | Retention of documentation relating to conformity assessments and custom-made devices |
| 10 | UK(NI) indication under Regulation (EU) 2017/745 |
| 10B | Retention of documentation relating to conformity assessments |
| 10C | UK(NI) indication under Regulation (EU) 2017/746 |
| 11 | Ethical review of clinical investigations |
| 12(1) | Prior authorisation of clinical investigations by the Secretary of State |
| 14 | Damage compensation in relation to clinical investigations |
| 15 | Retention of documentation relating to clinical investigations |
| 17C | Ethical review of performance studies |
| 17E | Damage compensation in relation to performance studies |
| 17F | Retention of documentation relating to performance studies] |
Textual Amendments
F1Sch. 3 Table 1 substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(a)
Table 2
| Article | Title of the article |
|---|---|
| 5(1) to (3), (5) | Placing on the market and putting into service |
| 6(1)-(3) | Distance sales |
| 7 | Claims |
| 9(3), (4) | Common specifications |
| 10 (except in paragraph 14, only the first sub-paragraph) | [F2general obligations of manufacturers] |
| 11(1), (3), (6) | Authorised representative |
| 12 | Change of authorised representative |
| 13 | General obligations of importers |
| 14 | General obligations of distributors |
| 15 | Person responsible for regulatory compliance |
| 16(3), (4) | Cases in which obligations of manufacturers apply to importers, distributors or other persons. |
| 17(1) | Single-use devices and their reprocessing |
| 18(1) | Implant card and information to be supplied to the patient with an implanted device |
| 21(2) | Devices for special purposes |
| 22(1), (3) to (5) | Systems and procedure packs |
| 23(1) | Parts and components |
| 25(1), (2) | Identification within the supply chain |
| [F332(1) (except the second sentence of the third sub-paragraph), (2)] | Summary of safety and clinical performance |
| 52(1) to (4), (6) to (11), (13) | Conformity assessment procedures |
| 53(3) | Involvement of notified bodies in conformity assessment procedures |
| 58(1) | Voluntary change of notified body |
| 62(1), (2) (only the first sub-paragraph), (3) (only the first sub-paragraph), (4), (5), (7) | General requirements regarding clinical investigations conducted to demonstrate conformity of devices |
| 82(1) | Requirements regarding other clinical investigations |
| 84 | Post-market surveillance plan |
| 85 | Post-market surveillance report |
| [F486 (except the second and third sentences of paragraph (2))] | Periodic safety update report |
| 89(1), (3) (only the second sub-paragraph),(5), (8) | Analysis of serious incidents and field safety corrective actions |
| 94 (only the final paragraph) | Evaluation of devices suspected of presenting an unacceptable risk or other non-compliance |
Textual Amendments
F2Words in Sch. 3 Table 2 substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(b)(i)
F3Words in Sch. 3 Table 2 substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(b)(ii)
F4Words in Sch. 3 Table 2 substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(b)(iii)
[F5Table 3
| Article | Title of the article |
|---|---|
| 5(1) to (3), (5) | Placing on the market and putting into service |
| 6(1) to (3) | Distance sales |
| 7 | Claims |
| 9(3) | Common specifications |
| 10 (except the second, third or fourth sub-paragraphs of paragraph 13) | General obligations of manufacturers |
| 11(1), (3), (6) | Authorised representative |
| 12 | Change of authorised representative |
| 13 | General obligations of importers |
| 14 | General obligations of distributors |
| 15 | Person responsible for regulatory compliance |
| 16(3), (4) | Cases in which obligations of manufacturers apply to importers, distributors or other persons |
| 20(1) | Parts and components |
| 22 | Identification within the supply chain |
| 29(1) (except the second sentence of the third sub-paragraph), (2) | Summary of safety and performance |
| 48(1), (2), (3) (except the third sub-paragraph), (4) (except the second sub-paragraph), (7) (except the third sub-paragraph), (8) (except the second sub-paragraph), (9) and (10) | Conformity assessment procedures |
| 49(3) | Involvement of notified bodies in conformity assessment procedures |
| 53(1) | Voluntary change of notified body |
| 57 | General requirements regarding performance studies |
| 58(1), (2), (4) (except the second sub-paragraph), (5), (6) and (8) | Additional requirements for certain performance studies |
| 79 | Post-market surveillance plan |
| 80 | Post-market surveillance report |
| 81 (except the second and third sentences of paragraph (2)) | Periodic safety update report |
| 84(1), (3) (except the first sub-paragraph), (5) and (8) | Analysis of serious incidents and field safety corrective actions |
| 89 (only the final paragraph) | Evaluation of devices suspected of presenting an unacceptable risk or other non-compliance] |
Textual Amendments
F5Sch. 3 Table 3 inserted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(c)
Options/Help
Print Options
PrintThe Whole Instrument
PrintThis Schedule only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
See additional information alongside the content
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Opening Options
Different options to open legislation in order to view more content on screen at once
Explanatory Memorandum
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as enacted version that was used for the print copy
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
Timeline of Changes
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as made version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.